Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SK12 is a preclinical-stage live biotherapeutic product (LBP) being developed by Zhiyi Pharmaceutics for the treatment of inflammatory skin conditions, including atopic dermatitis and psoriasis. As an LBP, SK12 consists of live microorganisms designed to provide a therapeutic effect, likely by modulating the host immune system or restoring microbial homeostasis. The program is currently in the preclinical development phase, with the company aiming to submit an Investigational New Drug (IND) application in the fourth quarter of 2029.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SK12.